Intervacc

Stockholm, February 13, 2024 - Intervacc AB (publ) will publish the year-end report 2023 on Friday 16 February 2024 at 08:30 CET. CEO Jonas Sohlman and CFO Jan Persson will present the report at a conference call and audiocast held on 16 February 2024 at 11:00 CET.

If you wish to participate, please use the link below.

https://financialhearings.com/event/49867

For more information please contact:  

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600, Cell: +46 (0) 70 576 30 73

E-mail: jonas.sohlman@intervacc.se

The information was submitted for publication, through the agency of the contact person set out above on February 13, 2024, 13.00 p.m. CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Sciences where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 - 684 211 10